Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Biodel Reports Protective Effects of VIAject(TM) Insulin on Microvascular Function in Patients with Type 2 Diabetes
Nov 15, 2008 08:31 AM
- Biodel Receives Notice of Allowance for Insulin Patent Claims in Europe
Oct 13, 2008 07:02 AM
- Biodel Announces Timing of FDA Discussions on VIAject(TM)
Oct 10, 2008 07:02 AM
- Biodel Announces Preliminary Results of Pivotal Phase III Clinical Trials for VIAject(TM)
Sep 08, 2008 03:01 AM
- Biodel to Report Results of VIAject(TM) Pivotal Phase III Clinical Trials at EASD Conference
Sep 03, 2008 04:32 PM
- Biodel Inc. Reports Third Quarter Fiscal Year 2008 Financial Results
Aug 06, 2008 04:01 PM
- Biodel Inc. to Announce Third Quarter Fiscal Year 2008 Financial Results on August 6, 2008
Jul 31, 2008 04:04 PM
- Biodel Announces Publications Demonstrating Superior Metabolic Profile of VIAject(TM) Compared to the Rapid-acting Analog Humalog(R) and Regular Human Insulin in Healthy Volunteers and Compared to Regular Human Insulin in Patients with Type 1 Diabetes
Jul 23, 2008 04:31 PM
- Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
Jul 16, 2008 07:09 PM
- Barry Ginsberg, M.D., Ph.D. Elected to Biodel's Board of Directors
Jun 11, 2008 08:31 AM
Analyst Ratings
|
|
Share Performance
|
Period
|
BIOD
|
Compare to S&P
|
| YTD |
-88.16 %
|
-80.61 %
|
| 4 Weeks |
23.87 %
|
33.90 %
|
| 12 Weeks |
-83.86 %
|
-77.63 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 0.00 %
|
|
EPS Growth in Last Year: -104.76 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
|
